Shopping Cart
Remove All
Your shopping cart is currently empty
Grisnilimab setaritox (Synonyms: WT1-RTA)
Catalog No. T82259 Copy Product Info
🥰Excellent
Grisnilimab setaritox (WT1-RTA), an anti-CD7 antihuman T cell antibody linked to ricin A chain (RTA), exhibits in vitro cytotoxicity against CEM (T-lymphoblastic leukemia) cells with an ID 50 of 53 pM. The 30-kDa RTA component disrupts the function of 60S ribosomal subunits. Additionally, Grisnilimab setaritox has demonstrated efficacy in ameliorating leukemic meningitis in a rhesus monkey model [1].
Grisnilimab setaritox
Copy Product Info🥰Excellent
Catalog No. T82259
Synonyms WT1-RTA
Grisnilimab setaritox (WT1-RTA), an anti-CD7 antihuman T cell antibody linked to ricin A chain (RTA), exhibits in vitro cytotoxicity against CEM (T-lymphoblastic leukemia) cells with an ID 50 of 53 pM. The 30-kDa RTA component disrupts the function of 60S ribosomal subunits. Additionally, Grisnilimab setaritox has demonstrated efficacy in ameliorating leukemic meningitis in a rhesus monkey model [1].
Grisnilimab setaritox
Cas No. 2361013-29-6
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Storage & Solubility Information
| Description | Grisnilimab setaritox (WT1-RTA), an anti-CD7 antihuman T cell antibody linked to ricin A chain (RTA), exhibits in vitro cytotoxicity against CEM (T-lymphoblastic leukemia) cells with an ID 50 of 53 pM. The 30-kDa RTA component disrupts the function of 60S ribosomal subunits. Additionally, Grisnilimab setaritox has demonstrated efficacy in ameliorating leukemic meningitis in a rhesus monkey model [1]. |
| In vitro | Grisnilimab setaritox (2.5 μg/mL; 24 h) exhibits cytotoxicity against T-lymphoblastic leukemia CEM cells [1]. |
| In vivo | Grisnilimab setaritox (60 μg, 120 μg; intrathecal or intravenous injection; single dose) demonstrated potential in inhibiting T-ALL meningeal leukemia in a rhesus macaque model [1]. Additionally, grisnilimab setaritox (60 μg; intravenous injection; once weekly for six weeks, or daily for seven days) induced CSF granulocytosis and anti-immunotoxin antibodies in the same model [1]. |
| Synonyms | WT1-RTA |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | CD7 |
| Cas No. | 2361013-29-6 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Grisnilimab setaritox | purchase Grisnilimab setaritox | Grisnilimab setaritox cost | order Grisnilimab setaritox | Grisnilimab setaritox in vivo | Grisnilimab setaritox in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.